09.10.2016 Views

LIFESTYLE

2dLZ0MO

2dLZ0MO

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Chai Cancer Care<br />

Together Magazine 2016<br />

Dr Christopher<br />

McNamara is<br />

a consultant<br />

haematologist in the<br />

lymphoma service<br />

at University College<br />

London Hospital.<br />

He completed post-graduate<br />

training in Australia and France<br />

before appointment as consultant<br />

haematologist at the Royal Free,<br />

London in 2004. He moved to UCLH<br />

in 2015. His interests are clinical<br />

trials, radioimmunotherapy and the<br />

interface between the laboratory and<br />

lymphoma patients. He has served on<br />

several guideline development groups<br />

for the European Society of Medical<br />

Oncology, the British Council for<br />

Standardisation in Haematology and<br />

for the national Institute for Clinical<br />

Health and Excellence, where he<br />

served as clinical lead for the national<br />

lymphoma guideline.<br />

Lymphoma<br />

therapy update<br />

We know more than ever about how cancer<br />

of the blood behaves and which treatments<br />

will produce the best outcomes. Consultant<br />

haematologist Christopher McNamara looks<br />

ahead to future developments<br />

Lymphoma is the most common<br />

type of blood cancer affecting<br />

people in the UK. There are many<br />

different types of lymphoma but they<br />

all generally occur when a certain<br />

type of blood cell no longer obeys the<br />

normal control signals that govern the<br />

growth of cells and tissues of the body.<br />

The diseased cells or lymphocytes<br />

aggregate together and typically<br />

spread through vessels connecting<br />

lymph nodes.<br />

A significant amount of research<br />

work has been done to understand the<br />

differences between the different types<br />

of lymphoma. This work, culminating<br />

in a classification system adopted<br />

by the World Health Organisation,<br />

has made important advances in the<br />

way in which lymphoma research is<br />

carried out and in the way in which<br />

people who suffer from lymphoma are<br />

treated. Increasingly, lymphomas are<br />

categorised according to molecular and<br />

genetic changes within the abnormal<br />

lymphoma cells. These genetic changes<br />

influence the way in which the cancer<br />

cells multiply and often how they will<br />

respond to treatment. Understanding<br />

these genetic changes has already led<br />

to significant improvements in the<br />

treatments available for lymphoma<br />

patients and is likely to radically<br />

reform further these approaches<br />

in the future.<br />

“Understanding genetic<br />

changes has already<br />

led to significant<br />

improvements in the<br />

treatments available”<br />

GENES HOLD THE KEY<br />

Many people are surprised when they<br />

hear that the laboratory is the first<br />

and perhaps most important step in<br />

the journey that a lymphoma patient<br />

will begin. The reason for that is<br />

that an accurate diagnosis is critical<br />

for obtaining the best outcome for<br />

a patient; the treatments used, as<br />

mentioned, frequently differ according<br />

to which lymphoma subtype a person<br />

has. It is, therefore, essential that<br />

material from a biopsy be looked at<br />

by an expert pathology doctor. In the<br />

future it is likely that genetic changes<br />

within the first biopsy sample will be<br />

used for all patients to direct which<br />

treatment should be given, even within<br />

the same lymphoma subtype. In<br />

other words, patients with the same<br />

lymphoma subtype will be treated<br />

differently, according to the molecular<br />

changes in their lymphoma.<br />

CHEMO AND<br />

CHEMO-FREE THERAPY<br />

Importantly, the outcome for<br />

lymphoma patients has been improving<br />

in recent times. Twenty years ago<br />

there was concern that, in spite of the<br />

availability of effective treatments, the<br />

overall survival for lymphoma patients<br />

was not improving. That has now<br />

changed. With effective combinations<br />

and information gleaned from properly<br />

conducted clinical trials, effective<br />

therapies that are given to people<br />

with lymphoma today have shown<br />

unequivocally that outcomes have<br />

improved compared with treatments<br />

used as recently 20 years ago.<br />

There is a range of different treatments<br />

available to patients in the UK.<br />

Chemotherapy remains an effective and<br />

generally well-tolerated treatment for<br />

most people. However, it is also fair to<br />

say that there is increasing interest in<br />

‘chemotherapy-free’ based approaches<br />

to managing lymphoma. Frequently,<br />

people affected by lymphoma have<br />

other medical problems, which<br />

preclude intensive treatment or they’re<br />

present at a point in their lymphoma<br />

journey where they are significantly<br />

debilitated and de-conditioned by<br />

the lymphoma itself. This makes<br />

the administration of chemotherapy<br />

sometimes difficult. In addition,<br />

we know from longitudinal studies<br />

that many patients who complete<br />

chemotherapy are affected by long-term<br />

physical, psychological and emotional<br />

problems that are most likely due to<br />

their chemotherapy.<br />

“Treatments by mouth<br />

generally don’t require<br />

admission to hospital<br />

and are very well<br />

tolerated”<br />

Many centres around the world are<br />

interested in this ‘chemotherapy-free’<br />

strategy whereby new drugs other<br />

than chemotherapy are used to induce<br />

a response. A new immunotherapy<br />

involving antibodies directed at<br />

special markers on the surface of<br />

cancer cells called antigens is already<br />

in clinical practice and thousands of<br />

patients have benefited from this<br />

and lives have certainly been saved<br />

as a consequence.<br />

The clinic has also seen the<br />

development of new medicines, which<br />

inhibit signalling inside cancer cells.<br />

These medications have changed the<br />

landscape in some lymphoma subtypes<br />

and are likely to have a significant<br />

impact upon lymphoma therapy in<br />

the future. These treatments can be<br />

taken by mouth, generally don’t require<br />

admission to hospital and are very well<br />

tolerated. They work by penetrating<br />

the lymphoma cell and turning off<br />

the machinery that the cell needs<br />

to survive and prosper.<br />

One of the advantages of these<br />

medications is that they typically<br />

don’t bring with them many of the<br />

chemotherapy-related side effects.<br />

Nausea, vomiting and hair loss are not<br />

common from these drugs and they<br />

often produce very good results, even in<br />

patients who have previously failed to<br />

respond to chemotherapy. It is important<br />

that ongoing research is carried out<br />

to define the longer-term safety and<br />

effectiveness of these agents, but<br />

preliminary studies are very exciting.<br />

There remains a strong desire to<br />

continue to improve the outlook for<br />

people and families not only affected by<br />

lymphoma but also to try and reduce<br />

the short- and long-term side effects of<br />

therapy. Clinical trials that are currently<br />

underway are likely to contribute to the<br />

answer to this question. ■<br />

The next leap forward:<br />

refining treatments<br />

• Molecular differences in<br />

their lymphoma subtype<br />

will mean patients<br />

with the same type<br />

of cancer will receive<br />

different treatments<br />

• Oral treatments<br />

will become more<br />

common<br />

• Advances in<br />

treatments will mean<br />

patients won’t need<br />

to be hospitalised<br />

24<br />

Together 2016<br />

Chai Cancer Care<br />

25

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!